GlobeNewswire

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia

Share
  • The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone
  • Roche will submit the REMDACTA results to a peer-reviewed journal

Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc.

Roche will continue to evaluate data from the REMDACTA, COVACTA and EMPACTA studies as well as other studies of Actemra/RoActemra in COVID-19 pneumonia. The EMPACTA study met its primary endpoint, while COVACTA did not meet its primary endpoint. Both were recently published in the New England Journal of Medicine.

“Given the global impact of COVID-19 pneumonia on patients, we are disappointed that the REMDACTA study did not meet its endpoints,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “We continue to believe that the totality of data suggests a potential role for Actemra in treating certain patients with COVID-19, and will discuss the results with health authorities. We thank our partners at Gilead, and all the patients, investigators and healthcare professionals for their participation.”

REMDACTA did not meet key secondary endpoints, which included likelihood of death, likelihood of progression to mechanical ventilation or death, and clinical status. The full results of the trial will be submitted for publication in a peer-reviewed journal later this year.

Actemra/RoActemra is not approved for the treatment of COVID-19 pneumonia.

The antiviral medication Veklury was invented and developed by Gilead Sciences and is approved or authorized for temporary use for the treatment of COVID-19 in approximately 50 countries worldwide.

For more information on how Roche is responding to the global COVID-19 pandemic, please visit our COVID-19 response page.

About the REMDACTA Trial
REMDACTA is a two-armed global phase III, randomised, double-blind, multicentre study (REMDACTA, NCT04409262) to evaluate the efficacy and safety of Actemra/RoActemra plus Veklury, versus placebo plus Veklury in hospitalised patients with severe COVID-19 pneumonia receiving standard of care. Veklury is an antiviral medicine that works to stop replication of SARS-CoV-2, the virus that causes COVID-19. The REMDACTA trial is being conducted in collaboration with Gilead Sciences, Inc. The primary endpoint of the study is improvement in time to hospital discharge by Day 28. Key secondary endpoints include likelihood of death, likelihood of progression to mechanical ventilation or death, and clinical status. Clinical status is measured by the 7-category ordinal scale, which tracks patients’ clinical status based on the need for intensive care and/or ventilator use, as well as supplemental oxygen requirements. Patients will be followed for 60 days post-randomisation.

About the COVACTA Trial
COVACTA is a global, randomised, double-blind, placebo-controlled phase III study (COVACTA, NCT04320615) which evaluated the safety and efficacy of intravenous Actemra/RoActemra added to standard of care in adult patients hospitalised with severe COVID-19 pneumonia compared to placebo plus standard of care. The primary and secondary endpoints included clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables. Patients were followed for 60 days post-randomisation.

About the EMPACTA Trial
EMPACTA (Evaluating Minority Patients with Actemra) is a phase III, randomised, double-blind, placebo-controlled multicentre study (EMPACTA, NCT04372186) which evaluated the efficacy and safety of Actemra/RoActemra in the treatment of hospitalised COVID-19 pneumonia among patients that are often underrepresented in clinical trials.

The primary endpoint was the cumulative proportion of participants dying or requiring mechanical ventilation by Day 28. Secondary endpoints included: time to clinical failure, defined as the time to death, mechanical ventilation, ICU admission, or withdrawal (whichever occurs first); mortality rate by Day 28; and time to hospital discharge or “ready for discharge.”

About Actemra/RoActemra
Actemra/RoActemra was the first approved anti-IL-6 receptor biologic, and is available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). Actemra/RoActemra can be used alone or with methotrexate (MTX) in adult RA patients who are intolerant to, or have failed to respond to, other disease-modifying anti-rheumatic drugs (DMARDs). In Europe, RoActemra IV and SC are also approved for use in adult patients with severe, active and progressive RA who previously have not been treated with MTX. Actemra/RoActemra IV and SC are also approved globally for polyarticular juvenile idiopathic arthritis (pJIA) and systemic juvenile idiopathic arthritis (sJIA) in children two years of age and older. Actemra/RoActemra SC is approved globally for giant cell arteritis (GCA), and Actemra/RoActemra IV is approved for the treatment of chimeric antigen receptor (CAR) T-cell-induced severe or life-threatening cytokine release syndrome (CRS) in people two years of age and older. Actemra/RoActemra was the first approved treatment for sJIA, GCA and CRS. Actemra SC is now approved in the U.S. for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). In addition to the above-mentioned indications, in Japan Actemra IV is also approved for the treatment of Castleman’s disease and adult Still's disease, and the Actemra SC formulation is approved for Takayasu arteritis. Actemra/RoActemra is part of a co-development agreement with Chugai Pharmaceutical Co., Ltd and has been approved in Japan since April 2005. Actemra/RoActemra is approved in more than 110 countries worldwide.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.


Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release

•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and

Interim Report January-March 202122.4.2021 18:30:00 CEST | Press release

First quarter 2021 Net profit for the first quarter amounted to MSEK 44.6 (-4.0).Earnings per share amounted to SEK 4.00 (-0.35).Net asset value amounted to MSEK 703 (SEK 63.04 per share) at March 31, 2021, compared to MSEK 679 (SEK 60.87 per share) at March 31, 2020.Net cash amounted to MSEK 180 (SEK 16.16 per share) at March 31, 2021, compared to MSEK 219 (SEK 19.65 per share) at December 31, 2020.The 2021 Annual General Meeting resolved to pay a dividend of 3.00 SEK per share for FY 2020. Comments by the CEO NAXS experienced a steady development during the first quarter of 2021 with the NAV/share increasing by 8.5%, including the dividend paid out. During the quarter, NAXS made a second co-investment alongside JAB Holding, this time in Krispy Kreme Doughnuts, the world-famous doughnut brand. As to the underlying funds, they acquired 4 new portfolio companies and signed or closed 4 exits during the quarter. In addition, a partial exit took place with the listing of Kreate on Nasdaq H

Prosafe SE: Supporting statement to the 2020 Annual Report in light of the ruling in the Westcon matter22.4.2021 18:30:00 CEST | Press release

Reference is made to Prosafe's annual accounts for 2020 published on 25 March 2021 as well as the notice for annual general meeting published on 12 April 2021. Reference is further made to announcement on 15 April 2021, in which Prosafe informed that the Gulating Court of Appeal had decided against Prosafe in the Westcon matter, thereby awarding full payment to Westcon of amounts claimed and thus reversing the ruling by the Stavanger District Court in the first instance. In light of the ruling, Prosafe has today issued a supporting statement to its 2020 annual report and accounts. The statement is attached. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 22 April 2021 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO

Delårsrapport januari – mars 202122.4.2021 18:30:00 CEST | Pressemelding

Första kvartalet 2021 Resultat efter skatt uppgick till 44,6 (-4,0) MSEK.Resultatet per aktie uppgick till 4,00 (-0,35) SEK.Substansvärdet uppgick till 703 MSEK (63,04 SEK per aktie) per den 31 mars 2021, jämfört med 679 MSEK (SEK 60,87 per aktie) per den 31 december 2020. Nettokassan uppgick till 180 MSEK (16,16 SEK per aktie) per den 31 mars 2021, jämfört med 219 MSEK (19,65 SEK per aktie) per den 31 december 2020.Årsstämman 2021 beslutade att lämna en utdelning om 3,00 SEK per aktie. VD-kommentar NAXS utvecklades positivt under första kvartalet och substanvärdet per aktie ökade med 8,5% inklusive lämnad utdelning. Under första kvartalet gjorde NAXS ytterligare en saminvestering parallellt med JAB Holding, denna gång i Krispy Kreme Doughnuts verksamt i USA. Vad gäller underliggande fonder förvärvade dessa 4 nya portföljbolag och undertecknade eller genomförde 4 exit under perioden. Vidare genomfördes en partiell exit genom börsnotering av Kreate på Nasdaq Helsingfors. NAXS lämnade un

Conagen’s Novel Solution to Making Natural Capsaicin by Fermentation Accessible22.4.2021 18:23:30 CEST | Press release

Bedford, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Scalable, sustainable capsaicin ingredients for its use in food, consumer and industrial products have now become more accessible. Conagen announced it has successfully scaled-up its fermentation process for the production of premium capsaicin and its related capsaicinoid molecules. Chili peppers are widely used as a food additive in spicy and hot cuisines, due to its hot and pungent characteristics. Consumers globally are demanding more clean, natural and exciting flavors, especially hot and spicy flavors. Yet, the challenge in meeting this demand is that capsaicin from chili peppers is difficult to use because of its hot properties, proposing challenges to manufacturers. Capsaicin extraction is limited by the availability of chili peppers, which is subject to fluctuations in price and quality. The market for capsaicin is growing because of its pungent characteristic, which is very versatile in a broad spectrum of applications, includ

OREGE: Annual results 2020 and outlook22.4.2021 18:05:00 CEST | Press release

PRESS RELEASE Voisins Le Bretonneux, 22 April 2021 – 6 PM ANNUAL RESULTS 2020 AND OUTLOOK ___________________________________________________________________ Summary financial information for the year ended December 31 2020. Strong growth in turnover which validates the commercial approach taken by Orege in recent years 15% decrease in net operating expenses, thanks to savings on the Group's fixed costs. (Consolidated financial statements approved by the board of directors on 21 April 2021. The audit procedures by the statutory auditors are being finalized.) In k€ - IFRS2020 2019 Turnover2 006935Net operating expenses:Payroll costs-3 334-3 814Operating expenses:Manufacturing, sub-contracting-980-1 816Travel and subsistence expenses-532-829Leasing and maintenance-431-460Other operating expenses-1 334-1 510Depreciation-511-54Amortization-744 -781 Total net operating expenses- 7 866- 9 264Operating loss-5 860-8 329Net financial loss-1 563-1 859Corporation tax--Net loss-7 423 -10 188 Turno

Wolters Kluwer Annual General Meeting of Shareholders adopts all resolutions22.4.2021 17:25:00 CEST | Press release

Wolters Kluwer Annual General Meeting of Shareholdersadopts all resolutions April 22, 2021 –Wolters Kluwer, a global provider of professional information, software solutions, and services,is pleased to announce that all resolutions were adopted as proposed at today’s Annual General Meeting. Reappointment of members of the Supervisory Board and member of the Executive Board Frans Cremers and Ann Ziegler were reappointed as members of the Supervisory Board and Kevin Entricken was reappointed as member of the Executive Board. The Supervisory Board members represent a diversity of nationality, experience, talent, and expertise. Three (43%) of the seven Supervisory Board members are female, in line with Dutch corporate governance standards and proposed legislation. 2020 Financial Statements and dividend Shareholders voted to adopt the Financial Statements for 2020 as included in the 2020 Annual Report and approved a total dividend of €1.36 per ordinary share, resulting in a final dividend o